Ankylosing spondylitis
From the Journals
Reduced TNFi dose does not maintain axial spondyloarthritis improvement
Patients with axial spondyloarthritis whose TNFi dose was reduced showed more disease flares and no changes in infection rates compared with those...
Conference Coverage
Advances in ankylosing spondylitis hailed as rheumatology’s story of the year
MAUI, HAWAII – The likely approval of oral JAK inhibitors is predicted to transform the AS treatment paradigm.
From the Journals
HLA-B27 status predicts radiographic phenotype of axSpA
Study findings from ankylosing spondylitis and axial psoriatic arthritis patients emphasize “the importance of HLA-B27 status in severity and the...
Conference Coverage
Meta-analysis highlights safety concerns with interleukin inhibition
MAUI, HAWAII – Increased risks seen for serious infections, cancer, and opportunistic infections.
Guidelines
New guideline offers recommendations for reproductive health in patients with rheumatic diseases
Among its many recommendations, the guideline strongly advises that women with RMD considering pregnancy switch to pregnancy‐compatible medication...
From the Journals
Anti–TNF-alpha nonresponse in axSpA predicted by socioeconomic, patient-reported factors
A study of patients in the BSRBR-AS “emphasizes that examination of predictors of nonresponse to pharmacologic therapy in inflammatory arthritis...
Feature
In rheumatology, biosimilars are flatlining. Why?
The United States hasn’t yet been able to reap the cost savings seen in Europe – for a host of reasons.
From the Journals
TNFi treatment shows hint of slowing axial spondyloarthritis radiographic progression
But no effects on slowing spine or sacroiliac joint progression were seen in eight studies of NSAIDs and in one study of secukinumab.
Conference Coverage
Repeat LTBI testing best in patients taking biologics with new risk factors
ATLANTA – Just 1.2% of patients taking biologics with negative tuberculosis test results converted to positive results in annual tuberculosis...
News from the FDA/CDC
FDA approves infliximab-axxq for numerous indications
This is the fourth biosimilar for this tumor necrosis factor inhibitor to receive FDA approval.
Commentary
Evidence grows for early axSpA treatment, uveitis flare prevention
Findings from the C-axSpAnd and C-VIEW studies of certolizumab pegol show the importance of short symptom duration in...